| Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer CR Ferrone, G Marchegiani, TS Hong, DP Ryan, V Deshpande, ... Annals of surgery 261 (1), 12-17, 2015 | 869 | 2015 |
| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 802 | 2020 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276-282, 2018 | 685 | 2018 |
| Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, MI D’Angelica, DE Abbott, DA Anaya, R Anders, C Are, ... Journal of the National Comprehensive Cancer Network 19 (5), 541-565, 2021 | 628 | 2021 |
| Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial JE Murphy, JY Wo, DP Ryan, W Jiang, BY Yeap, LC Drapek, ... JAMA oncology 4 (7), 963-969, 2018 | 545 | 2018 |
| New horizons for precision medicine in biliary tract cancers JW Valle, A Lamarca, L Goyal, J Barriuso, AX Zhu Cancer discovery 7 (9), 943-962, 2017 | 531 | 2017 |
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ... Cancer discovery 7 (3), 252-263, 2017 | 469 | 2017 |
| Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic … TS Hong, JY Wo, BY Yeap, E Ben-Josef, EI McDonnell, LS Blaszkowsky, ... Journal of Clinical Oncology 34 (5), 460-468, 2016 | 450 | 2016 |
| Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial JE Murphy, JY Wo, DP Ryan, JW Clark, W Jiang, BY Yeap, LC Drapek, ... JAMA oncology 5 (7), 1020-1027, 2019 | 435 | 2019 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 415 | 2019 |
| Targeting the HGF/c-MET pathway in hepatocellular carcinoma L Goyal, MD Muzumdar, AX Zhu Clinical Cancer Research 19 (9), 2310-2318, 2013 | 350 | 2013 |
| AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma AG Singal, JM Llovet, M Yarchoan, N Mehta, JK Heimbach, LA Dawson, ... Hepatology 78 (6), 1922-1965, 2023 | 337 | 2023 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 291 | 2019 |
| Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre … M Javle, S Roychowdhury, RK Kelley, S Sadeghi, T Macarulla, KH Weiss, ... The Lancet Gastroenterology & Hepatology 6 (10), 803-815, 2021 | 278 | 2021 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 275 | 2021 |
| Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions T Hato, L Goyal, TF Greten, DG Duda, AX Zhu Hepatology 60 (5), 1776-1782, 2014 | 259 | 2014 |
| Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ... Clinical Cancer Research 27 (20), 5586-5594, 2021 | 239 | 2021 |
| Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... New England Journal of Medicine 388 (3), 228-239, 2023 | 233 | 2023 |
| Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway OPR Hamnvik, TK Choueiri, A Turchin, RR McKay, L Goyal, M Davis, ... Cancer 121 (2), 311-319, 2015 | 226 | 2015 |
| Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study MA Lowery, HA Burris, F Janku, RT Shroff, JM Cleary, NS Azad, L Goyal, ... The lancet Gastroenterology & hepatology 4 (9), 711-720, 2019 | 203 | 2019 |
